Over the past decades, clinical trials have been demonstrated that IL-17A blockade as a monotherapy lacks good clinical efficacy in RA (32, 33), implying that not all IL-17A–producing Th17 cells induce inflammation and promote disease development. This evidence concerns the gene IL17A and rheumatoid arthritis.